Veradigm Inc. (MDRX)
After hours:
| Previous close | 13.00 |
| Open | 13.16 |
| Bid | 13.38 x 3100 |
| Ask | 13.50 x 1000 |
| Day's range | 13.08 - 13.39 |
| 52-week range | 12.98 - 23.25 |
| Volume | |
| Avg. volume | 1,173,005 |
| Market cap | 1.461B |
| Beta (5Y monthly) | 1.01 |
| PE ratio (TTM) | 15.73 |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | 07 Oct 2008 |
| 1y target est | N/A |
- Business Wire
Veradigm Practice Management Ranks First in Practice Management Solutions from Black Book™ Research
CHICAGO, March 14, 2023--Veradigm® (NASDAQ: MDRX), a leading provider of healthcare data and technology solutions, announced today that Black Book, a healthcare-centric market research and public opinion research and consulting company, has ranked Veradigm Practice Management first for its 2023 Practice Management Solutions, 50+ Physician Groups category.
- Business Wire
Veradigm Inc. Update on 4th Quarter and Full Fiscal Year 2022 Reporting of Results
CHICAGO, February 28, 2023--Veradigm Inc. (NASDAQ: MDRX), announced today that in conjunction with its year-end audit procedures it has detected certain internal control failures related to revenue recognition that have occurred over the prior six quarters, resulting in a mis-statement to reported revenues during those periods. As a result, the Company and its external auditors need to expand procedures and are filing with the SEC a Form 12b-25, extending the due date of the Company’s Form 10-K
- Business Wire
Veradigm Announces Two New Appointments to Its Board
CHICAGO, February 22, 2023--Susan Rodriguez and Shih-Yin Ho, MD have been named to the Board of Directors of Veradigm Inc. (NASDAQ: MDRX). With their combined experience in the pharmaceutical industry, digital health, and healthcare, together they bring a wealth of experience to Veradigm, to help build upon the company’s vision of transforming health, insightfully.
